Imfinzi (mono/combo)

2026-05-22 — AstraZeneca announced it will present extensive oncology and rare disease data at the ASCO Annual Meeting (May 29–June 2, 2026), with 85+ abstracts covering 10 approved and 13 potential medicines and 25 oral presentations.

Key late-stage highlights include EMERALD-3 (Phase III) in unresectable, embolization-eligible hepatocellular carcinoma, evaluating IMFINZI (durvalumab) + IMJUDO (tremelimumab-actl) with or without lenvatinib plus TACE (late-breaking oral abstract). In breast cancer, SERENA-6 (Phase III) will report final PFS2 and ctDNA clearance data for camizestrant + CDK4/6 inhibitors in 1L HR+/HER2− disease with emergent ESR1 mutations; DESTINY-Breast09 and TROPION-Breast02 (both Phase III) will add 1L metastatic breast cancer analyses for ENHERTU and DATROWAY, respectively.

In rare disease, CARES (Phase III) will present results for anselamimab (Alexion, AstraZeneca Rare Disease) in AL amyloidosis, emphasizing potential clinically meaningful benefit and a prespecified κ/λ subgroup analysis. AstraZeneca noted its collaboration with Daiichi Sankyo on ENHERTU and DATROWAY, supporting pipeline and potential commercial expansion.